Nir Tomer

Dr. Nir Tomer

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2020 in Bladder Cancer
Verified
Journal Article
Open access
PDF file
JPJohn L. Pfail
John L. Pfail
FAFrançois Audenet
François Audenet
AMAlberto Martini
Alberto Martini
NTNir Tomer
Nir Tomer
IPIshan Paranjpe
Ishan Paranjpe
JSJohn P. Sfakianos
John P. Sfakianos
PURPOSE: Data have indicated that residual disease after neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) may be associated with poor outcomes. OBJECTIVE: Analyze differences in overall survival (OS) of patients with residual MIBC treated with NAC + Radical cystectomy (RC), RC alone, or RC + Adjuvant Chemotherapy(AC). MATERIALS AND METHODS: The National Cancer Database was queried for patients who underwent RC alone, NAC + RC, or RC + AC for MIBC stage cT2-4aN0M0 from 2004-2015. Covariates were balanced using propensity score (PS) weighting. Time to death was evaluated from diagnosis. Weighted cox proportional hazards models and Kaplan-Meier survival curves were created to analyze differences in OS. RESULTS: 8,288 patients were included for analysis, 1,899 (23%) received NAC + RC, 5,529 (67%) received RC alone, and 860 (10%) received RC + AC. Patients were sub-stratified based on pathological staging (≤pT2 or >pT2) and compared against treatment with RC alone. In the ≤pT2 cohort, NAC + RC was associated with a decreased risk of death (HR:0.85, 95% CI:0.79–0.91) and RC + AC was associated with an increased risk of death (HR:1.46, 95% CI:1.34–1.60, both p < 0.001) compared to RC alone. In the >pT2 cohort, these associations reversed, with an increased risk of death seen in the NAC + RC group (HR:1.11, 95% CI:1.05–1.18) and a decreased risk of death in the RC + AC group (HR:0.74, 95% CI:0.7–0.77, both p < 0.001). CONCLUSIONS: Patients with >ypT2 disease after NAC experienced a significant increased risk of death when compared to pathological stage-matched patients who underwent RC alone or RC + AC. Biomarkers predictive of NAC resistance may be important to optimize NAC usage and establish treatment algorithms.

Verified
Journal Article
Open access
PDF file
NTNir Tomer
Nir Tomer
VDVinay Durbhakula
Vinay Durbhakula
KGKavita Gupta
Kavita Gupta
RKRaymond Khargi
Raymond Khargi
BGBlair Gallante
Blair Gallante
MGMantu Gupta
Mantu Gupta
Background: Percutaneous nephrolithotomy is the gold standard treatment for large, complex intrarenal stones. Historically, this was performed using a nephrostomy tube (PCN) and/or internalized ureteral stent at the end of the procedure. However, totally tubeless nephrolithotomy (tt-PCNL) is a novel technique where no tubes (no stent nor nephrostomy tube) are left post-operatively. We review the literature on this subject regarding peri-operative outcomes, post-operative outcomes, and potential complications of the procedure, discuss our technique, and make recommendations on implementation for centers not currently utilizing the procedure. Materials and methods: We performed a comprehensive search of the literature on totally tubeless nephrolithotomy using MEDLINE database search. Our search included prior review articles, meta-analyses, systematic reviews, primary research articles, case reports, and case studies. Results: In comparison to prior approaches where a stent or nephrostomy tube is placed, tt-PCNL has a similar complication rate and better post-operative outcomes. Totally tubeless PCNL has similar operative times and similar changes in hemoglobin. However, it had shorter length of stays across all studies. The mean difference in length of stay in the studies reviewed was 1.96 days. Additionally, tt-PCNL had decreased post-operative analgesic requirements and pain scores. Conclusions: This review highlights totally tubeless percutaneous nephrolithotomy as a safe and feasible surgical technique with improved outcomes in properly selected patients.

1 January 2022 in Urology Practice
Verified
Journal Article
Closed access
MLMicah Levy
Micah Levy
EGEvan B. Garden
Evan B. Garden
NTNir Tomer
Nir Tomer
OAOsama Al-Alao
Osama Al-Alao
ASAlexander C. Small
Alexander C. Small
MPMichael A. Palese
Michael A. Palese
Purpose:Erectile dysfunction (ED) and benign prostatic hyperplasia (BPH) are frequently managed with medications. Variability and poor understanding of medication prices have been shown to ...

1 April 2021 in Transplantation Proceedings
Verified
Journal Article
Closed access
NTNir Tomer
Nir Tomer
ASAlexander Small
Alexander Small
OMOmar Mirza
Omar Mirza
MPMichael Palese
Michael Palese

18 September 2024 in Urology Practice
Verified
Journal Article
Closed access
NTNir Tomer
Nir Tomer
JKJohnathan Alexander Khusid
Johnathan Alexander Khusid